Macau SAR, China regulator grants approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in patients with BCG-unresponsive NMIBC with CIS ± papillary tumors Authorization follows a reliance-based ...
Food and Drug Administration approval in April 2024 for use in combination with BCG in BCG-unresponsive NMIBC CIS with or without papillary tumors and was assigned a permanent J-code (J9028) by the ...
This is your brain on AI, according to new research ...People relying on them so heavily that their own thinking begins to splinter ... Matthew Kropp, another coauthor of the study and a BCG managing director, described the trend as an early warning sign.
) Liberty Global to Present at the NewStreet Research and BCGGlobal Connectivity Leaders Conference...LBTYA, LBTYB and LBTYK) will be presenting at the NewStreet Research and BCG Global Connectivity ...
The long-term safety and efficacy results for ANKTIVA plus BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumors have been published in The Journal of Urology.
OpenAI partners with four major consulting firms in multi-year FrontierAlliance deal to scale enterprise AI agent deployments globally. (Read More) ... .